Show simple item record

dc.contributor.authorOgdie, Alexis
dc.contributor.authorHaynes, Kevin
dc.contributor.authorTroxel, Andrea B
dc.contributor.authorLove, Thorvardur Jon
dc.contributor.authorHennessy, Sean
dc.contributor.authorChoi, Hyon
dc.contributor.authorGelfand, Joel M
dc.date.accessioned2014-08-29T13:56:18Z
dc.date.available2014-08-29T13:56:18Z
dc.date.issued2014-01
dc.date.submitted2014
dc.identifier.citationAnn. Rheum. Dis. 2014, 73 (1):149-53en
dc.identifier.issn1468-2060
dc.identifier.pmid23264338
dc.identifier.doi10.1136/annrheumdis-2012-202424
dc.identifier.urihttp://hdl.handle.net/2336/325566
dc.description.abstractThere are conflicting reports in the literature of the mortality risk among patients with psoriatic arthritis (PsA). The objective of this study was to examine the risk of mortality in patients with PsA compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA).
dc.description.abstractA longitudinal cohort study was performed in a large UK medical record database, The Health Improvement Network, among patients with PsA, rheumatoid arthritis (RA) or psoriasis with data from 1994 to 2010. Unexposed controls were matched on practice and start date within the practice for each patient with PsA. Cox proportional hazards models were used to calculate the relative hazards for death.
dc.description.abstractPatients with PsA (N=8706), RA (N=41 752), psoriasis (N=138 424) and unexposed controls (N=82 258) were identified; 1 442 357 person-years were observed during which 21 825 deaths occurred. Compared with population controls, patients with PsA did not have an increased risk of mortality after adjusting for age and sex (disease-modifying antirheumatic drug (DMARD) users: HR 0.94, 95% CI 0.80 to 1.10; DMARD non-users: HR 1.06, 95% CI 0.94 to 1.19) whereas patients with RA had increased mortality (DMARD users: HR 1.59, 95% CI 1.52 to 1.66; DMARD non-users: HR 1.54, 95% CI 1.47 to 1.60). Patients with psoriasis who had not been prescribed a DMARD had a small increased risk of mortality (HR 1.08, 95% CI 1.04 to 1.12) while those who had been prescribed a DMARD, indicating severe psoriasis, were at increased risk (HR 1.75, 95% CI 1.56 to 1.95).
dc.description.abstractPatients with RA and psoriasis have increased mortality compared with the general population but patients with PsA do not have a significantly increased risk of mortality.
dc.description.sponsorshipAmerican College of Rheumatology Clinical and Translational Science Award at the University of Pennsylvania from the National Center for Research Resources/8UL1TR000003 NIH/T32 GM075766-05 American College of Rheumatology Research and Education Foundation Icelandic Research Fund /120433021/R01AG025152 R01HL111293en
dc.language.isoenen
dc.publisherBmj Publishing Groupen
dc.relation.urlhttp://dx.doi.org/10.1136/annrheumdis-2012-202424en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883139/en
dc.relation.urlhttp://ard.bmj.com/content/73/1/149.full.pdf+htmlen
dc.rightsArchived with thanks to Annals of the rheumatic diseasesen
dc.subjectSóríasisen
dc.subjectGigtarsjúkdómaren
dc.subjectIktsýkien
dc.subjectÁhættuþættiren
dc.subjectTíðnien
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshArthritis, Psoriaticen
dc.subject.meshArthritis, Rheumatoiden
dc.subject.meshCohort Studiesen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshIncidenceen
dc.subject.meshLongitudinal Studiesen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshProportional Hazards Modelsen
dc.subject.meshPsoriasisen
dc.subject.meshRisk Factorsen
dc.subject.meshYoung Adulten
dc.titleRisk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.en
dc.typeArticleen
dc.contributor.departmentUniv Penn, Ctr Clin Epidemiol & Biostat, Ctr Pharmacoepidemiol Res & Training, Div Rheumatol,Perelman Sch Med, Philadelphia, PA 19104 USA, Univ Penn, Ctr Clin Epidemiol & Biostat, Ctr Pharmacoepidemiol Res & Training, Dept Biostat & Epidemiol,Perelman Sch Med, Philadelphia, PA 19104 USA, Landspitali Univ Hosp, Div Rheumatol, Reykjavik, Iceland, Boston Univ, Sch Med, Rheumatol Sect, Boston, MA 02118 USA, Boston Univ, Sch Med, Clin Epidemiol Unit, Boston, MA 02118 USA, Univ Penn, Ctr Clin Epidemiol & Biostat, Ctr Pharmacoepidemiol Res & Training, Dept Dermatol,Perelman Sch Med, Philadelphia, PA 19104 USAen
dc.identifier.journalAnnals of the rheumatic diseasesen
dc.rights.accessLandspitali Access - LSH-aðganguren
html.description.abstractThere are conflicting reports in the literature of the mortality risk among patients with psoriatic arthritis (PsA). The objective of this study was to examine the risk of mortality in patients with PsA compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA).
html.description.abstractA longitudinal cohort study was performed in a large UK medical record database, The Health Improvement Network, among patients with PsA, rheumatoid arthritis (RA) or psoriasis with data from 1994 to 2010. Unexposed controls were matched on practice and start date within the practice for each patient with PsA. Cox proportional hazards models were used to calculate the relative hazards for death.
html.description.abstractPatients with PsA (N=8706), RA (N=41 752), psoriasis (N=138 424) and unexposed controls (N=82 258) were identified; 1 442 357 person-years were observed during which 21 825 deaths occurred. Compared with population controls, patients with PsA did not have an increased risk of mortality after adjusting for age and sex (disease-modifying antirheumatic drug (DMARD) users: HR 0.94, 95% CI 0.80 to 1.10; DMARD non-users: HR 1.06, 95% CI 0.94 to 1.19) whereas patients with RA had increased mortality (DMARD users: HR 1.59, 95% CI 1.52 to 1.66; DMARD non-users: HR 1.54, 95% CI 1.47 to 1.60). Patients with psoriasis who had not been prescribed a DMARD had a small increased risk of mortality (HR 1.08, 95% CI 1.04 to 1.12) while those who had been prescribed a DMARD, indicating severe psoriasis, were at increased risk (HR 1.75, 95% CI 1.56 to 1.95).
html.description.abstractPatients with RA and psoriasis have increased mortality compared with the general population but patients with PsA do not have a significantly increased risk of mortality.


This item appears in the following Collection(s)

Show simple item record